Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Sara Bastian
Kantonsspital Graubünden
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
38
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
First-Line Durvalumab in Patients with Pd-L1 Positive, Advanced Non-Small Cell Lung Cancer (Nsclc) with a Performance Status of 2 (Ps2). Primary Analysis of the Multicenter, Single-Arm Phase Ii Trial Sakk 19/17
Number of pages: 20
Posted: 27 Sep 2023
Michael Thomas Mark
,
Patrizia Froesch
,
Katrin Gysel
,
Sacha I. Rothschild
,
Alfredo Addeo
,
Christoph Ackermann
,
Sabrina Chiquet
,
Martina Schneider
,
Karin Ribi
,
Angela Fischer
, Sara Bastian,
Roger Von Moos
,
Markus Joerger
and
Martin Früh
Kantonsspital Graubünden, Oncology Institute of Southern Switzerland, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, University of Basel - University Hospital Basel, University of Geneva - Department of Oncology, Spital Thun, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Kantonsspital Graubünden, Kantonsspital Graubünden, Kantonsspital Graubünden, Cantonal Hospital of St. Gallen and Cantonal Hospital of St. Gallen
Downloads
38
(1,222,651)
View PDF
Download
Abstract:
immunotherapy, first-line, metastatic non-small cell lung cancer, performance status 2
Feedback
